McLAREN, Christine, E.;ARIZONA BOARD OF REGENTS ON BEHALF OF UNIVERSITY OF ARIZONA;THE REGENTS OF THE UNIVERSITY OF C;MEYSKENS, Frank, L.;ZELL, Jason;RAJ, Kavitha, P.;JACOB, Jeffrey;GERNER, Eugene, W.
Controlling exogenous polyamines may be used, in some aspects, as an adjunctive strategy to chemoprevention with polyamine inhibitory agents, for example, anti-carcinoma combination therapies comprising ornithine decarboxylase (ODC) inhibitor and a spermidine/spermine N1-acetyltransferase expression agonist, optionally based on a patient's ODC1 promoter genotype. Assessing a tissue polyamine level or tissue polyamine flux may be used in some aspects, for predicting the efficacy of an anti-carcinoma combination therapy comprising, for example, an ornithine decarboxylase (ODC) inhibitor and an agent that modulates the polyamine pathway to reduce overall cellular polyamine content.
